SAFETY AND EFFICACY OF THE FITUSIRAN REVISED ANTITHROMBIN-BASED DOSE REGIMEN IN PEOPLE WITH HAEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORS (ATLAS-OLE)
Guy-Younga, Kaan-Kavaklib, S W-Pipec, Alok-Srivastavad,e, Juliana-Aragaof, L A-Menapaceg, Chuanwu-Zhangh, Marja-Puuruneng, Marek-Demissieg, Gili-Keneti
a Hemostasis and Thrombosis Center, Cancer and Blood Disease Institute, Children's Hospital Los Angeles (CHLA), University of Southern California, Los Angeles, CA 90027, USA
b Department of Pediatric Hematology and Oncology, Ege University Faculty of Medicine Children's Hospital, Izmir, Turkey
c Departments of Pediatrics and Pathology, University of Michigan (UM), Ann Arbor, MI
d Department of Haematology, Christian Medical College (CMC), Vellore India
e Centre for Stem Cell Research (CSCR), inStem, Vellore, India
f Sanofi Medley Farmaceutica Ltda, Suzano, Sao Paulo, SP, Brazil
g Sanofi, Cambridge, MA, USA
h Sanofi, Waltham, MA, USA
i The National Hemophilia Centre, The Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Ramat Gan, Israel
Ver másLido
538
Vezesque se leu este artigo
134
Total PDF
404
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 31 | 11 | 42 |
| 2025 5 | 77 | 12 | 89 |
| 2025 4 | 55 | 11 | 66 |
| 2025 3 | 58 | 11 | 69 |
| 2025 2 | 55 | 13 | 68 |
| 2025 1 | 35 | 13 | 48 |
| 2024 12 | 32 | 19 | 51 |
| 2024 11 | 43 | 21 | 64 |
| 2024 10 | 18 | 23 | 41 |
